Table 1.
Demographic and baseline characteristics.
| Colorectal cancer (n = 2798) |
Non-colorectal cancer (n = 204) |
Total (N = 3005a) |
|
|---|---|---|---|
| Age, median (IQR), years | 60.0 (52.0-67.0) | 58.0 (52.5-67.0) | 60.0 (52.0-67.0) |
| Age group, n (%) | |||
| <65 years | 1811 (64.7) | 139 (68.1) | 1952 (65.0) |
| ≥65 years | 987 (35.3) | 65 (31.9) | 1053 (35.0) |
| Male, n (%) | 1658 (59.3) | 135 (66.2) | 1795 (59.7) |
| Chinese, n (%) | 2798 (100.0) | 204 (100.0) | 3005 (100.0) |
| BMI | |||
| N (missing) | 2751 (47) | 202 (2) | 2956 (49) |
| Median (IQR), kg/m2 | 22.6 (20.3-24.9) | 21.1 (19.0-23.8) | 22.6 (20.2-24.8) |
| Pathologic type, n (%) | |||
| Adenocarcinoma | 2703 (96.6) | 162 (79.4) | 2868 (95.4) |
| Mucinous carcinoma | 19 (0.7) | 2 (1.0) | 21 (0.7) |
| Undifferentiated carcinoma | 0 | 1 (0.5) | 1 (0.0) |
| Other | 76 (2.7) | 39 (19.1) | 115 (3.8) |
| Tumor metastasis | |||
| N (missing) | 2259 (539) | 101 (103) | 2362 (643) |
| Liver, n (%) | 1660 (73.5) | 73 (72.3) | 1733 (73.4) |
| Lung, n (%) | 1200 (53.1) | 36 (35.6) | 1238 (52.4) |
| Liver and lung, n (%) | 601 (26.6) | 8 (7.9) | 609 (25.8) |
| Time from initial diagnosis to study enrollment | |||
| N (missing) | 2783 (15) | 204 (0) | 2990 (15) |
| Median (IQR), months | 21.5 (13.1-36.4) | 7.5 (0.1-21.5) | 20.8 (12.2-35.7) |
| Time from initial diagnosis to first dose of fruquintinib | |||
| N (missing) | 2783 (15) | 204 (0) | 2990 (15) |
| Median (IQR), months | 21.4 (13.1-36.2) | 7.5 (0.1-21.2) | 20.7 (12.1-35.7) |
aIncluded 3 patients who had unknown primary tumors: patient 1 had an unknown origin, likely gastrointestinal tract, with lung metastasis; patient 2 had abdominal metastasis of unknown primary tumor; patient 3 had multicentric intestinal adenocarcinoma with peritoneal, lymph node, and lung metastasis.
Abbreviations: BMI, body mass index; IQR, interquartile range.